How Much Weight Can You Lose on a GLP-1? Realistic Results, by the Numbers

"How much weight will I actually lose?" is the first question almost everyone asks about these drugs, and it's the one most likely to get answered with either hype or a shrug. The honest answer is a range, not a number — but it's a well-studied range, with real trial data behind it, and understanding the full picture (not just the headline average) is what separates a realistic plan from a disappointment. This guide is the numbers, straight: what the trials found, how much of that carries into real life, how fast it happens, and what moves your own result up or down the scale.

We'll be precise and we'll be honest, which on this topic means saying clearly that the eye-popping averages come from controlled trials where people got the full dose and structured support, that your mileage will vary, and that a meaningful minority of people respond far less than the average — because knowing that upfront is how you set expectations you can actually meet. Where a figure comes from a specific trial, we name it and link it, so you can check the primary research rather than trust a number off a landing page.

Two framing points before the data. First, weight-loss results are almost always expressed as a percentage of starting body weight, not pounds, because that's how the trials measure it and because it scales to your size — "15% of body weight" means very different pounds for a 300-pound person than a 180-pound one. We'll translate to pounds where it helps. Second, these are, for most people, long-term treatments: the numbers below are what the drug can do while you're on it, and maintaining the loss is its own topic we'll cover near the end. With that, the headline question.

How much weight can you lose on a GLP-1?

Here are the headline averages from the pivotal trials — the numbers behind every "people lost X%" claim you've seen. These are averages at the full therapeutic dose over the trial length, in people with obesity or overweight-plus-a-condition.

Averages from each drug's pivotal trial, not head-to-head except where noted; your result depends on dose, adherence, and biology. Pound figures are illustrative, from a 220-lb starting weight. Sources linked in each drug's section below.

So the one-line answer: a typical person loses somewhere between about 11% and 21% of their body weight on these drugs at full dose over roughly a year to 18 months, with tirzepatide at the top of that range and the oral options toward the bottom. That's genuinely large — it's the kind of weight loss that used to require surgery, which is why these drugs changed obesity medicine. But three things complicate that clean number, and they're the difference between a realistic expectation and a letdown: the average hides a wide spread, real life underperforms the trials, and the result depends on what you do. We'll take each in turn, starting with what each specific drug actually delivers.

Results by drug: the trial numbers

"A GLP-1" isn't one result — the drugs differ, sometimes substantially. Here's what each pivotal trial actually found.

Semaglutide (Wegovy) — about 15%

Semaglutide 2.4 mg, the Wegovy injection, is the drug that started the modern era. In its pivotal STEP 1 trial, adults with obesity or overweight-plus-a-condition lost an average of 14.9% of body weight at 68 weeks, compared with just 2.4% on placebo (STEP 1, NEJM 2021). For context, roughly 86% of participants lost at least 5% of their weight, about 69% lost 10% or more, around 50% lost 15% or more, and about a third lost 20% or more — a useful reminder that "15% average" contains a lot of people above and below it. Fifteen percent is the number to anchor on for semaglutide, and it's enough to meaningfully improve blood pressure, blood sugar and other health markers.

Tirzepatide (Zepbound) — about 21%, the current leader

Tirzepatide, the Zepbound injection, adds a second hormone mechanism (GIP alongside GLP-1) and is the most powerful option on weight loss to date. In its pivotal SURMOUNT-1 trial, adults without diabetes lost an average of about 21% of body weight at the 15 mg dose over 72 weeks (SURMOUNT-1, NEJM 2022), with some analyses of trial completers running higher. The responder distribution is striking: roughly nine in ten participants lost at least 10%, about 78% lost 15% or more, more than half lost 20% or more, and about 36% lost 25% or more. In head-to-head testing, tirzepatide has outperformed semaglutide (roughly 20% vs 14% in a direct comparison). If maximum weight loss is the priority, tirzepatide leads.

The oral options — about 11–14%

The newer pills land a step below the strongest injections, which is the honest trade for not using a needle. Oral semaglutide 25 mg (the Wegovy pill) averaged about 13.6% in its OASIS 4 trial, rising to roughly 16.6% among people who adhered to its strict dosing rules (OASIS 4, NEJM 2025). Orforglipron (Foundayo), the first oral small-molecule GLP-1, averaged about 11–12% at its top dose in the ATTAIN-1 trial (ATTAIN-1, NEJM 2025). Still clinically meaningful double-digit loss — just not injection-level. Our guide to the GLP-1 pill covers the oral options in depth.

Ozempic and Mounjaro (the diabetes brands)

These are the same molecules (semaglutide and tirzepatide) branded for type 2 diabetes. Weight loss on them tends to run somewhat lower than the dedicated weight-loss brands, partly because of different dosing, but they produce meaningful loss, and for someone with diabetes they're often the covered, affordable path. The weight-loss numbers above (Wegovy, Zepbound) are the ones to use for weight-loss expectations.

How that compares to the alternatives

To put the numbers in perspective: lifestyle changes alone typically produce an average of a few percent of body weight that's hard to sustain; older weight-loss pills generally landed in the mid-single digits to low double digits; and bariatric surgery produces roughly 25–30%. The GLP-1s slot in between the old pills and surgery — and tirzepatide, at around 21%, pushes into territory that used to require an operation. That's the real significance of these numbers: they're not a marginal improvement on dieting, they're a different tier of result.

It's worth dwelling on just how large the jump is, because familiarity has dulled it. Before these drugs, a weight-loss medication that reliably produced 5% average loss was considered a genuine success, and most people trying to lose weight through diet and exercise alone regained most of it within a few years — not through lack of effort, but because the body defends its weight. A drug that produces 15–21% average loss, sustained while taken, isn't an incremental step along that old path; it's a break from it. That's why the medical conversation around obesity shifted so fast, and why the honest framing of "how much can you lose" starts from a genuinely remarkable baseline — even before we get into the nuance of distributions and real-world results that fills the rest of this guide.

The drugs side by side: a data scorecard

For the data-minded, here's the fuller statistical picture in one place — not just the averages, but the responder bands that show how many people hit each milestone. These come from the pivotal trials and are approximate; they're the honest way to see your odds at each level of result.

Approximate responder rates from STEP 1 (NEJM 2021) and SURMOUNT-1 (NEJM 2022) at the top doses; exact figures vary with analysis method. Oral options (not shown) run below both, around 11–14% average.

Read down the responder columns and the real story of these drugs appears. On tirzepatide, hitting 10% isn't the good outcome — it's the typical one, reached by about nine in ten people, and even 20% is more likely than not. On semaglutide the whole distribution sits lower but is still remarkable by historical standards: half of people clear 15%. This is also the clearest way to see the gap between the two drugs: at every threshold, tirzepatide's share is higher, which is what "tirzepatide is more effective" actually means in numbers. If you're choosing between them on results alone, this table is the argument — though cost, tolerability and whether you'll stay on it matter too, as our comparison lays out.

One honest caveat on reading these: trial responder rates come from people who stayed in the trial at the full dose with support. Your personal odds of hitting each band improve the more you look like a trial participant — full dose, consistent use, good habits — and slip if you stop early or under-dose. The table shows what's achievable; your execution determines which column of odds you actually play.

These bands are also the most honest answer to "will it work for me," better than any single average. An average of 21% can read as a promise; the bands read as odds, which is what they really are. On tirzepatide, your odds of clearing 10% are excellent, your odds of clearing 20% are better than a coin flip, and your odds of a surgery-rivalling 25%+ are roughly one in three — real possibilities, none guaranteed. Framing your expectations as odds rather than a target does something useful psychologically: it makes a result anywhere in the distribution feel like a draw from a favorable deck rather than a pass/fail against a line. You're playing good odds, not chasing a fixed number, and that's both the accurate way to think about it and the kind of expectation you can actually live with.

Does your starting weight change how much you lose?

A common and sensible question: if results are measured in percentages, does a heavier person lose more, less, or the same? The answer has a few useful parts.

In percentage terms, results are fairly consistent across a wide range of starting weights. The drugs produce roughly similar percentage loss whether you start at 200 pounds or 300 — that's why trials report percentages, because they travel well across body sizes. So a 15% or 21% average is a reasonable expectation regardless of whether you're at the lower or higher end of the eligible range.

But in absolute pounds, a higher starting weight means more pounds lost. This is just arithmetic: 20% of 320 pounds (64 lb) is a lot more weight than 20% of 200 pounds (40 lb). For someone starting heavier, the same percentage delivers a larger, often more visible, change on the scale — which can be motivating, and which is part of why people with more to lose sometimes report the most dramatic journeys.

Where you finish matters as much as how much you lose. A person starting at a lower weight may reach a healthy BMI with a 15% loss, while someone starting much heavier may lose 25% and still have further to go. Neither is "better" — they're different starting points on the same percentage math. Setting your own goal around where you want to land, in consultation with a clinician, is more useful than fixating on a percentage or a pound count in isolation.

There's a motivational wrinkle worth knowing, too. Because heavier starting weights produce larger pound losses for the same percentage, people who begin with more to lose often see faster, more visible early changes — bigger numbers on the scale, clothes changing sooner — which can be genuinely encouraging. The flip side is that someone starting closer to a healthy weight may see smaller absolute numbers and feel like "it's not working," when in percentage terms they're doing just as well. If you're in the second group, switch your attention from the pound count to the percentage and to how you feel and fit; the drug is likely working exactly as expected, just expressed in smaller absolute numbers. Judging your progress in the right unit is half the battle against unwarranted discouragement.

The practical takeaway: expect the percentage averages to apply to you roughly regardless of your size, translate that to pounds for your own starting weight to set a realistic target, and judge success by your health and where you land rather than by comparing your pound total to someone who started at a very different place. Percentage is the honest unit; pounds is how you'll feel it.

You are not the average: the full distribution

Here's the single most important thing to understand about these numbers, and the thing hype articles skip: "average" means half of people did better and half did worse, and the spread is wide. Two people on the same drug at the same dose can have very different results, and that's biology, not effort.

Picture the SURMOUNT-1 tirzepatide results not as "21%" but as a distribution. A large group clustered around that average. A substantial minority — more than a third — lost 25% or more, results that rival surgery. And at the other end, a smaller group lost relatively little. The semaglutide trial shows the same shape around its lower average: about a third of people exceeded 20%, while some didn't clear 5%. The average is the center of a crowd, not a line everyone lands on.

To make the spread concrete: on tirzepatide, the gap between a strong responder and a weak one in the same trial can be the difference between losing a third of your body weight and losing almost none — same drug, same dose, same 72 weeks. That's a genuinely wide range, and it's why a single average number is such a poor guide to any individual's experience. The average is honest as a center of gravity; it's misleading as a personal forecast. Anyone who tells you "you'll lose 21%" is quoting a statistic as if it were a prediction, and the responsible version is always "the average is around 21%, you'll likely land somewhere in a wide band around it, and here's how to tilt the odds upward."

This matters for your expectations in two directions. If you're a strong responder, you might substantially beat the headline number — plenty of people do. But you should also plan for the possibility that you're a below-average responder, because someone has to be, and it isn't a personal failing. The practical move most clinicians use: reassess after you've been at the full dose for a few months. If you're responding, continue; if you're a genuine low-responder, that's a reason to adjust the plan — a different drug, a higher dose, added support — not to conclude the whole approach failed.

Non-responders: when a GLP-1 barely works

"Non-response" is usually defined as losing less than 5% of body weight after a fair trial at a therapeutic dose. In the clinical trials, non-response was fairly uncommon, especially on high-dose tirzepatide (single-digit percentages of participants). In the real world it's more common — some cohorts report roughly one in six people not reaching 5% — largely because real-world patients more often stop early, never reach the full dose, or have other factors in play. If a GLP-1 genuinely isn't working for you after an adequate trial, that's medically useful information: people respond differently to semaglutide versus tirzepatide, so a true non-responder on one sometimes responds well to the other. It's a conversation with your clinician, not a dead end.

Trial numbers vs real life: why your result may be lower

The trial averages are real, but they're a ceiling, not a typical outcome — and honesty requires saying that real-world weight loss generally runs lower than the trial figures, often landing in the high-single-digits to mid-teens rather than the trial's 15–21%. Why the gap? A few concrete reasons, all of which you can partly control:

• People don't reach the full dose. The trial averages are at the top therapeutic dose. In real life, many people stop titrating early — because of side effects, cost, or just not pushing to the maximum — and a lower dose generally means less weight loss. The headline number assumes you got all the way up.
• People stop early. Trials keep people on the drug for the full 68–72 weeks with support. In the real world, a large share of people discontinue within the first year — side effects, cost, access, or losing motivation — and weight loss stops (and often reverses) when the drug does.
• Less structured support. Trial participants get regular check-ins, counseling and monitoring. A prescription with no coaching is a weaker version of the trial conditions, and support meaningfully affects results.
• Different starting points. Trials enroll specific populations; your age, starting weight, metabolism, other medications and conditions all shift the result.

The encouraging flip side: the main reasons real-world results lag — stopping early and under-dosing — are partly in your control and your clinician's. Staying on the drug, titrating to an effective dose under guidance, and adding real lifestyle support are exactly how you move your own result from the disappointing end toward the trial numbers. That's most of what the "how to maximize results" section below is about.

The timeline: what to expect, month by month

Weight loss on a GLP-1 isn't linear, and knowing the shape of the curve prevents the two classic mistakes: panicking when early loss is slow, and giving up when a normal plateau arrives. Here's the general arc. It's a typical pattern, not a schedule for you specifically — your clinician's plan and your own response always govern.

Weeks 1–4: starting low, small changes

Every GLP-1 is started at a low dose and stepped up gradually over months — this is deliberate, to limit side effects, and it means the first few weeks are not where big weight loss happens. What many people do notice early is the appetite change: feeling full faster, thinking about food less, the quieting of "food noise." Weight loss in the first month is usually modest (a few pounds), and some of it is water. The early phase is about your body adjusting and the dose climbing, not dramatic scale movement. Nausea and other digestive effects, if they come, are also most common here and usually ease.

Months 2–5: the dose climbs, loss accelerates

As you titrate toward the full dose over roughly four to five months, weight loss generally picks up and becomes more noticeable. This is often the steepest part of the curve — the months where people see the clearest, most motivating results. A common rough pattern is losing a meaningful share of body weight through this stretch, though the exact pace varies widely. The key point: the drug gets more effective as the dose rises, so early-months results tend to understate where you're heading. Don't judge the drug by month one.

Months 6–12: steady progress toward the average

Through the back half of the first year, weight loss typically continues but gradually slows — still downward, just less steep. This is where people approach the trial-average territory if they've reached and stayed on an effective dose. By around 6 months, averages in the trials were already past the halfway mark of the eventual total; by 12 months, most of the loss has happened. Consistency is everything in this stretch: the people who hit the trial numbers are the ones who stayed on the drug and kept the habits going.

Months 12–18: approaching the plateau

Weight loss on a GLP-1 generally plateaus somewhere around 12 to 18 months, as the body reaches a new equilibrium at the given dose. This is normal and expected — it's where the trial averages were measured, and it's not a sign the drug "stopped working." Your weight stabilizing at a new, lower level is, in fact, the goal; the plateau marks the shift from losing to maintaining. We'll cover what the plateau means and what to do about it next.

Why you plateau — and what it means

The plateau confuses and frustrates people, so it's worth explaining properly, because misunderstanding it causes a lot of people to quit right when they should be shifting gears.

Your body actively defends its weight. As you lose, metabolism adapts (you burn somewhat fewer calories at a lower weight), and the appetite-regulating systems push back — this is the same biology that makes diets fail, and it's exactly what the drug is counteracting. A GLP-1 shifts your "set point" downward, but at any given dose there's a new equilibrium where the drug's appetite suppression and your body's defense balance out. When you reach it, weight loss stops. That's the plateau: not failure, but a new steady state.

What the plateau is not is a signal to stop the drug. If you stop, the appetite suppression lifts and weight tends to return. A plateau at a healthy new weight is a successful outcome to maintain, not a problem to solve by quitting. If, however, you plateau well short of your goal and still have meaningful weight to lose, that's a conversation with your clinician about options: confirming you're at an effective dose, tightening the lifestyle factors that still move the needle, considering a switch to a more powerful drug (semaglutide to tirzepatide, say), or accepting that this may be your body's realistic new set point for now. The plateau is a decision point, not an ending — and understanding that keeps people from throwing away months of progress at exactly the wrong moment.

Month-by-month: the numbers behind the curve

For the people who want the data, not just the shape, here's a more granular view of how weight loss typically accumulates — a composite drawn from the trial trajectories. Treat the percentages as rough, averaged guides; individual pace varies a lot, and your titration speed shifts the whole timeline.

*Rough composite from the pivotal-trial trajectories; the higher end reflects tirzepatide, the lower end semaglutide and the oral options. Your pace depends on drug, dose, titration speed and biology. Not a schedule — a general shape.

Notice the shape in the numbers: the pace isn't steady. The early months deliver a small share of the total, the middle months do the heavy lifting as the dose peaks, and the final stretch tapers toward the plateau. This is the opposite of what many people expect — they brace for fast early loss and steady decline, then feel something's wrong when the first weeks are slow and the later months slow again. Both are normal features of the curve, not deviations from it. Internalizing the real shape in advance is one of the most practical things in this guide, because it inoculates you against the two moments people most often quit: the slow start and the natural plateau.

Two lessons jump out of that table. First, the curve back-loads: if you only lost 3–5% by month two, that's normal and on track, not a failure — the bigger numbers come as the dose rises. Judging the drug at week six is the classic mistake. Second, most of the total lands in the first year, with the plateau arriving as the loss naturally tapers. Knowing this shape in advance is genuinely useful: it stops the early panic and the late-stage quit, which are the two points where people most often abandon a plan that was actually working.

One practical note on tracking against this curve: weight fluctuates day to day with water, food and hormones, so a single disappointing morning weigh-in tells you almost nothing. The trend over weeks is the signal; the daily number is noise. We cover how to track properly below.

What determines your results

If the average is a crowd and you want to land at the better end of it, these are the factors that actually move your number — some you control, some you don't, all worth understanding.

• The dose you reach. The biggest controllable factor. The trial averages are at the full therapeutic dose; stalling at a low dose generally means less loss. Reaching an effective dose, titrated carefully under guidance, is the single most important lever.
• Which drug. Tirzepatide outperforms semaglutide on average, and the injections outperform the pills. Drug choice alone can swing your expected result by several percentage points.
• Consistency and staying on it. Weight loss tracks time on an effective dose. People who stay the course hit the trial numbers; people who stop early or dose erratically don't. This is where most real-world results are lost.
• Protein and resistance training. These don't just protect muscle (critical — see below); adequate protein supports satiety and metabolism, and preserving muscle keeps your metabolic rate up, which supports continued loss. The drug plus strength training beats the drug alone.
• Diet quality, not just quantity. The drug reduces how much you eat; what you eat still matters for body composition, energy and health. People who use the appetite reduction to build better eating patterns do better than those who just eat less of the same.
• Sleep and stress. Both affect appetite hormones and weight regulation. Poor sleep and high stress work against the drug; addressing them helps it.
• Your starting point and biology. Starting weight, age, sex, genetics, other medications and conditions all influence response, and they're largely out of your control. This is why two people on identical regimens get different results — and why comparison to someone else's before-and-after is a trap.

It's worth being clear-eyed about the split between what you control and what you don't, because both halves matter. Biology sets the range you're playing in — your genetics, age, sex, starting metabolism and medical background put a ceiling and a floor on what's realistic, and no amount of effort fully overrides them. That's why two people doing everything "right" can still get different results, and why self-blame for a below-average response is misplaced. But within that biologically-set range, the controllable factors decide where you land, and the swing is large: the difference between a low dose taken erratically with no lifestyle support and a full dose taken consistently with protein, training and coaching can be the difference between a disappointing result and a trial-level one. You can't choose your range, but you largely choose your position within it — and most people have more room to move up than they use.

Notice how many of these are controllable. "Response to a GLP-1" sounds like pure luck, and biology does set a range — but within that range, the dose you reach, how long you stay on, and whether you pair the drug with protein, training and sleep genuinely move your result. The people at the top of the distribution aren't all just lucky; many did the controllable things well.

"Why am I not losing weight on a GLP-1?"

This is one of the most-searched GLP-1 questions, usually asked in frustration, and it almost always has a findable cause. If the scale isn't moving the way you expected, work through these before concluding the drug doesn't work for you.

• You're early, or not at full dose yet. The most common reason. If you're in the first month or two, or still titrating up, you simply haven't reached the drug's effective range. Early slow loss is normal — give it time and dose escalation before judging.
• You've hit a normal plateau. If you lost well and then stopped, you may have reached your equilibrium at the current dose. That's not "not working" — it's the expected plateau, and the fix (if you have more to lose) is a clinician conversation about dose or drug, not quitting.
• Your dose is too low. If you stalled early and well short of results, you may not be at an effective dose. Many people under-titrate; ask your clinician whether a careful increase is appropriate.
• Habits quietly drifted. The appetite reduction is powerful but not absolute. Liquid calories, grazing, and high-calorie foods can offset it. The drug makes eating less easier; it doesn't make the content of what you eat irrelevant.
• You're losing fat but the scale hides it. If you've added resistance training, you may be gaining muscle while losing fat, which the scale understates. Measurements, how clothes fit, and body-composition changes tell a truer story than weight alone.
• You're a genuine lower-responder. A minority of people respond less to a given GLP-1. If you've been at a full dose for a few months with good habits and still little result, that's real, and it's a reason to discuss switching drugs — not to blame yourself.
• Something else is in play. Certain medications, untreated conditions (thyroid, sleep apnea), high stress or poor sleep can blunt results. Worth reviewing with your clinician.

A useful mental check when the scale stalls: ask "has anything actually changed, or am I comparing to an unrealistic expectation?" Often the honest answer is that nothing's wrong — you're two months in and expected three months of loss, or you lost 14% and hoped for 20% that was never the average. Recalibrating to the real distribution resolves a surprising share of "it's not working" worries. When something genuinely has changed — loss that was steady then stopped well short of goal — that's the signal to investigate dose, habits and drug choice with your clinician. Distinguishing "working as expected but slower than I imagined" from "genuinely stalled below potential" is the key judgment, and it's one your prescriber can help you make with the data in front of you.

The throughline: "not losing weight" is usually either too-early, too-low-a-dose, a normal plateau, or drifted habits — all addressable — and only occasionally true non-response, which is itself actionable. Don't suffer in silence or quit in frustration; this is exactly what your prescriber is for.

Do results differ by group?

Weight-loss response varies between individuals far more than between neat demographic groups, and the trial averages apply broadly. But a few group-specific patterns and considerations are worth knowing, always as general tendencies rather than rules about any individual.

Women and men

Both lose substantial weight on these drugs, and the headline averages apply to both. Some analyses suggest women may lose a somewhat higher percentage on average, partly related to body composition differences, but the overlap is enormous and sex is a weak predictor compared with dose, adherence and biology. The far more important variable for anyone is reaching and staying on an effective dose.

Menopause and hormonal changes

Weight gain and stubborn weight around menopause is a common, real frustration, driven partly by hormonal shifts that affect appetite, fat distribution and metabolism. GLP-1s work through appetite regulation regardless of that hormonal backdrop, so they can be effective during and after menopause — though some women find the same determinants (sleep, stress, muscle loss with age) need extra attention to get the best result. It's a productive conversation to have with a clinician who understands both the medication and the hormonal picture.

Older adults

Older adults can lose weight effectively on GLP-1s, but muscle preservation becomes even more important with age, because age-related muscle loss plus rapid weight loss can meaningfully affect strength and function. Adequate protein and resistance training aren't optional add-ons here — they're central to a good outcome. Dosing and monitoring also warrant extra care in older patients. The weight-loss potential is real; the surrounding plan matters more.

People with type 2 diabetes

People with type 2 diabetes often lose somewhat less weight on GLP-1s than people without diabetes — a consistently observed pattern — even though the same drugs are highly valuable for them for blood-sugar control. If you have diabetes, calibrate your weight expectations a bit below the headline obesity-trial averages, while recognizing the drug is doing important metabolic work beyond the scale. The benefits beyond weight loss are a big part of the value here.

PCOS and insulin resistance

For people with PCOS or significant insulin resistance, weight loss is often a first-line goal because it improves many features of the condition, and GLP-1s can help — the appetite-and-insulin effects map well onto the problem. Response varies as it does for everyone, and it's an area of growing clinical interest rather than a formally established use for PCOS specifically, so it's a clinician conversation. The weight-loss expectations are broadly in line with the general averages.

People with a lot of weight to lose

For people starting at a high weight, the percentage averages still apply, which means the absolute pound losses can be very large and often very visible — a genuine advantage for motivation. The considerations that grow with starting weight are practical rather than about the percentage: the journey is longer (more total pounds to lose at a similar percentage pace), muscle preservation and loose skin become more relevant, and the health wins along the way are often substantial because higher starting weight usually means more weight-related conditions to improve. For this group especially, the long-term, maintenance-minded framing matters, because the destination is further out and the stakes — in both health gained and weight to keep off — are higher. It's also the group most likely to approach surgery-level results with the strongest drugs, which is worth discussing with a clinician who treats obesity.

How to track your results properly

How you measure progress shapes how you feel about it, and the scale alone is a famously unreliable narrator. Tracking well keeps you motivated through the normal bumps and tells you the truth about whether the drug is working.

Weigh consistently, but read the trend, not the day. Body weight swings two to four pounds or more day to day from water, food, sodium, hormones and bowel timing — none of it fat. A single up-morning means nothing. If you weigh, do it under the same conditions (same time, similar state) and watch the multi-week trend line, which smooths the noise. Many people find weighing less often, or focusing on a weekly average, far less maddening than a daily number.

Measure more than weight. A tape measure around the waist, how your clothes fit, and progress photos often reveal changes the scale hides — especially if you're preserving or building muscle while losing fat, which can keep weight flat while your body visibly changes. Body-composition tracking, where available, separates fat loss from muscle and is the truest measure, since the goal is losing fat, not just weight.

Watch the non-scale wins. Blood pressure, blood sugar, energy, mobility, sleep, how you feel on stairs — these improve with weight loss and are results in their own right, often arriving before big scale changes. For a chronic-disease treatment, they matter at least as much as the number.

Track against the curve, not against other people. Expect the back-loaded shape (slow start, faster middle, plateau), and judge your progress against that trajectory and your own baseline — not against a stranger's dramatic before-and-after, who started at a different weight, on a different drug, at a different dose, with a different body. Comparison to others is the fastest route to unwarranted discouragement on a journey that's working fine.

A simple system most people can sustain: weigh a few mornings a week under the same conditions and look only at the weekly average; take a waist measurement and a set of photos once a month; note how your clothes fit and your energy, sleep and any health markers your clinician tracks; and check all of it against the expected curve rather than against anyone else. That's enough signal to know whether you're on track and to catch a real stall, without the daily emotional whiplash. The goal of tracking is a clear, calm read on the trend — not a number to obsess over every morning, which for many people does more harm than good.

Tracking well isn't vanity or obsession — done right, it's the opposite. It replaces the anxiety of a noisy daily number with a clear read on the real trend, which is what keeps people on a plan long enough to get the results the trials promise.

The science of regain: why the body fights back

Understanding why weight returns after stopping — and why the plateau happens in the first place — turns a frustrating mystery into a manageable reality. It comes down to one idea: your body actively defends a weight it considers "normal," and that defense is powerful.

When you lose weight, two things happen that work against you. First, metabolic adaptation: your body burns somewhat fewer calories at a lower weight, partly because there's less of you and partly because the body down-regulates energy use in response to weight loss — a thrifty response wired in over evolution. Second, appetite hormones shift to increase hunger and reduce fullness, pushing you to eat more and regain. Together these defend a "set point," and they're exactly why most diets fail: lose weight, and your biology spends months or years trying to put it back.

A GLP-1 works by counteracting that appetite side of the defense — it keeps you full and quiets hunger, holding the line your biology is trying to push back. That's why it works while you take it, and why the plateau is where the drug's push and your body's push reach balance. And it's why stopping causes regain: remove the drug, and the appetite defense, which never went away, reasserts itself against a body that's also burning fewer calories. The follow-up to the STEP 1 trial — roughly two-thirds of lost weight regained within about a year of stopping — is this biology in a chart.

There's an important nuance that cuts against fatalism here: the regain isn't always total, and what you do affects it. In the follow-up data, people regained most but not all of their loss on average, and individuals varied — those who maintained strong habits, preserved muscle and stayed active generally held onto more. Stopping the drug removes the appetite suppression, but it doesn't erase the behaviors and body composition you built; a lower-muscle, no-plan cold stop regains fastest, while a supported taper with maintained strength and habits regains least. So "you'll gain it all back" is too pessimistic — the honest version is "most people regain much of it without the drug, and how much depends on the plan you stop with."

This is genuinely reframing, because it moves the conversation from willpower to physiology. Regaining weight after stopping isn't a moral failure or proof you "didn't really change"; it's the predictable result of removing a treatment for a chronic condition. We don't expect blood pressure to stay down after stopping blood-pressure medication, and obesity behaves similarly. The practical implications run through this whole guide: plan for the long term, protect muscle to blunt the metabolic-adaptation side (muscle keeps your burn higher), and treat stopping as a medical decision with a maintenance plan, not a finish line. The biology that defends your weight is the thing you're managing — ongoing — not a battle you win once.

How to get results at the better end of the range

You can't change your genetics, but you can stack the controllable factors in your favor. Here's what the people who hit or beat the trial numbers tend to do.

1. Reach and hold an effective dose. Work with your clinician to titrate up carefully to a dose that works, managing side effects along the way rather than stalling low. This is the number-one lever.
2. Stay on it. Results track time on an effective dose. Solve the things that make people quit — side effects (with titration and timing), cost (see our cost guide), access — so you can stay the course.
3. Prioritize protein. Adequate protein supports satiety, helps preserve muscle, and protects your metabolic rate. On a reduced appetite, making protein the priority at each meal matters more than ever.
4. Do resistance training. Lifting (or bodyweight work) is the single best defense against the muscle loss that comes with rapid weight loss, and preserving muscle keeps your metabolism higher, which supports continued fat loss and better maintenance.
5. Use the appetite window to build habits. The drug quiets cravings; use that calm to establish eating patterns you can keep, so your results don't depend on the drug alone forever.
6. Protect sleep and manage stress. Both move appetite hormones. They're easy to ignore and genuinely affect results.
7. Get real support. Coaching, check-ins and accountability move results — it's a big part of why trial participants did so well. A program with genuine support beats a bare prescription; we weigh exactly that in our rankings.

None of this is exotic, and that's the point: the drug does the hard part (appetite), and these habits capture the rest of the available result. The gap between a disappointing outcome and a trial-level one is usually not a secret — it's dose, consistency, protein, training and support, done steadily.

Keeping it off: what happens when you stop

The hardest truth about GLP-1 results is what happens when the drug stops, and any honest guide has to state it plainly. These drugs work while you take them; stop, and the weight tends to come back. In a well-known follow-up to the STEP 1 trial, participants who came off semaglutide regained about two-thirds of their lost weight within roughly a year. That's not a failure of willpower — it's the same biology the drug was counteracting reasserting itself: appetite returns, the body defends its higher set point, and without the medication the suppression is gone.

This reframes the whole "how much can you lose" question. The relevant number isn't just the peak loss; it's the weight you can sustain, and sustaining it usually means staying on some form of treatment long-term, the way you'd stay on blood-pressure or cholesterol medication for a chronic condition. Some people are able to step down to a lower maintenance dose; some maintain through intensive lifestyle change; many stay on a full dose. The research on stopping is clear enough that "lose the weight then quit the drug" is, for most people, a plan to regain.

None of this should read as discouraging, because the maintenance reality is the same for every effective obesity treatment, including surgery, and it doesn't diminish the value of the loss — it just defines what success looks like. Success isn't hitting a peak number on the scale and walking away; it's reaching a healthier weight and holding it, with ongoing treatment and habits, the way you'd manage any chronic condition. People who internalize that from the start — who see the drug as long-term care rather than a crash course — tend to both lose well and keep it off, precisely because they're not planning for a finish line that doesn't exist. The question "how much can I lose" quietly becomes "how much can I keep," and the second question is the one worth optimizing your whole approach around.

The practical implications: go in understanding this is likely long-term, factor the ongoing cost into your decision (our cost guide helps), build the muscle-preserving and habit foundations that give you the best shot at maintaining, and if you do need to stop, do it as a planned, supported taper with a maintenance strategy — not a cold stop. Our guide on what happens when you stop a GLP-1 goes deeper. The weight you keep is the number that actually matters, and keeping it is about the long game, not the peak on the scale.

Results beyond the scale: the health numbers

Weight is the headline, but it's not the only result these drugs deliver, and for a lot of people the health changes are the real prize. Judging a GLP-1 purely by the scale undersells what it's doing, so it's worth counting the other numbers that move.

As weight comes off — and in some cases partly independent of it — the trials and clinical experience consistently show improvements in the markers that drive long-term health: blood pressure tends to fall, blood sugar and A1c improve (often substantially in people with diabetes or prediabetes), cholesterol and triglycerides move in the right direction, and markers of inflammation drop. These aren't minor footnotes; they're the mechanisms by which weight loss reduces the risk of heart attack, stroke, diabetes and more. And the benefits start early and accrue steadily — many show up well before you reach your peak weight loss, which is part of why even a "modest" 5–10% loss is clinically valuable.

The reach extends further still. In large trials, semaglutide reduced the risk of major cardiovascular events in people with heart disease; GLP-1s have shown kidney benefits and are approved to treat obesity-related sleep apnea; and the class is being studied across the liver, the brain and more. Our dedicated guide, GLP-1s beyond weight loss, covers what's proven versus emerging in depth. The point for this guide is narrower but important: when you tally your "results," count the blood pressure that normalized, the A1c that dropped, the sleep that improved and the medications you may have been able to reduce — not just the pounds. For a treatment aimed at a chronic disease, those are the results that most change how long and how well you live.

This also reframes the disappointment some people feel when their scale result lands below the headline average. If you lost "only" 12% but your blood pressure normalized, your prediabetes reversed and you came off another medication, that is a profoundly successful outcome by any medical measure. The scale is one instrument on the dashboard; it's not the whole dashboard, and the best way to judge your results is across all of them.

There's also a timing lesson in the health numbers that helps during the slow early weeks. Some of these markers move before dramatic weight loss shows up — blood sugar and blood pressure can start improving within the first weeks to months, well ahead of the plateau. So if you're early in treatment and impatient with the scale, it's worth asking your clinician to check the numbers that may already be moving. Seeing your A1c or blood pressure trending down in month two, even while the scale is still catching up, is both genuine progress and powerful motivation to stay the course through the back-loaded weight curve. The scale is the slowest-moving instrument on the dashboard; several of the others respond sooner.

Common mistakes that cost people results

Most disappointing GLP-1 outcomes aren't bad luck — they're a handful of avoidable mistakes, repeated. Knowing them in advance is one of the cheapest ways to end up at the better end of the distribution.

• Quitting in the first month because loss is slow. The curve back-loads; early loss understates where you're headed. People who bail at week four quit a drug that hadn't started working yet. Give the dose time to climb.
• Stalling at a low dose. The trial averages are at the full therapeutic dose. Settling for a starter dose — out of inertia, side-effect fear, or cost — caps your result below what the drug can do. Titrate to an effective dose with your clinician.
• Stopping at the plateau. The plateau is a new equilibrium, not a failure, and it's often a healthy place to maintain. Quitting there usually means regain. If you have more to lose, adjust the plan; don't abandon it.
• Ignoring protein and strength training. Skip these and more of your loss is muscle, your metabolism drops, and both your results and your maintenance suffer. They're not optional extras — they're part of the treatment.
• Drinking your calories. The appetite suppression is powerful against food and weak against liquid calories — sugary drinks, alcohol, elaborate coffees. These quietly offset the drug. Easy to miss, easy to fix.
• Letting the daily scale run your mood. Daily weight is mostly noise. People who ride every fluctuation often quit on a bad-water day that meant nothing. Track the trend.
• Comparing yourself to someone else's before-and-after. Different starting weight, drug, dose and biology make most comparisons meaningless and discouraging. Judge against your own baseline and the expected curve.
• Treating it as a short course. Planning to "lose it and quit" sets up regain. Going in with a long-term, maintenance mindset is itself a predictor of keeping the weight off.

Read that list and notice none of it requires special genetics or luck — it's dose, patience, protein, training, sensible tracking and a long-term mindset. The people who get the trial-level results overwhelmingly avoided these traps, and avoiding them is entirely within reach.

Setting a realistic goal for yourself

All these numbers are only useful if you can turn them into a sensible personal target — one ambitious enough to matter and realistic enough to hit. Here's how to set one without either lowballing or setting up disappointment.

Start from the percentage, then translate to your pounds. Pick a realistic percentage based on your drug — roughly 15% as a central expectation on semaglutide, 20% on tirzepatide, a bit lower on the pills — and apply it to your starting weight to get a pound figure. For a 250-pound person on tirzepatide, 20% is 50 pounds; on semaglutide, 15% is about 38. That's your "central estimate," with real room above and below it.

Set a range, not a single number. Because the distribution is wide, a single target invites disappointment if you land just below it. A range — say, "somewhere between 12% and 22%" — honors the biology and keeps a result at the lower end from feeling like a failure. You might beat it; you might not reach the top; both are normal.

Anchor on health and where you'll land, not just the drop. A target BMI, getting off a medication, reversing prediabetes, or simply moving comfortably can be better goals than a pound count, because they capture why you're doing this. And even a result in the low teens, if it normalizes your blood pressure and blood sugar, is a win worth setting as a goal in its own right.

Build in the long view. The most useful goal isn't peak loss — it's a weight you can sustain, which means your target should assume ongoing treatment and habits, not a sprint to a number you then can't hold. A slightly more modest weight you keep beats a dramatic one you regain.

The healthiest mindset here is to aim for the middle of the realistic range, treat anything in the range as success, count the health wins alongside the pounds, and plan for the long term. Set the goal that way and you're aiming at something both meaningful and achievable — which is exactly the kind of goal people actually reach.

Frequently asked questions

How much weight can you lose on a GLP-1?

On average in the pivotal trials, about 15% of body weight on semaglutide (Wegovy) and about 21% on tirzepatide (Zepbound) over 15–17 months at full dose; the oral options (Wegovy pill, Foundayo) land around 11–14%. For a 220-pound person, that's roughly 33 pounds on semaglutide and 46 on tirzepatide. But averages hide a wide spread — some lose 25%+, a minority lose little — and real-world results typically run lower than the trial figures, mostly because people stop early or don't reach the full dose.

How much weight will I lose on Wegovy?

Semaglutide 2.4 mg (Wegovy) produced an average of 14.9% body-weight loss at 68 weeks in the STEP 1 trial. In that trial about 86% of people lost at least 5%, around 69% lost 10% or more, about half lost 15% or more, and roughly a third lost 20% or more. Your result depends on reaching the full dose, staying on it, and your own biology.

How much weight will I lose on Zepbound (tirzepatide)?

Tirzepatide is the most effective option, averaging about 21% body-weight loss at the 15 mg dose over 72 weeks in SURMOUNT-1 — with more than a third of participants losing 25% or more. It outperformed semaglutide in head-to-head testing (roughly 20% vs 14%). If maximum weight loss is your priority and you'll inject, tirzepatide leads.

How much weight will I lose on the GLP-1 pill?

The oral options land a bit below the strongest injections. Oral semaglutide (the Wegovy pill) averaged about 13.6% (up to ~16.6% among adherent users) in OASIS 4, and orforglipron (Foundayo) about 11–12% in ATTAIN-1 — both meaningful double-digit loss, traded for not using a needle.

How fast does a GLP-1 work?

Appetite often changes within the first weeks, but meaningful weight loss builds over months as the dose is titrated up. The fastest loss is usually in the middle months (roughly months 2–6 as you reach full dose), progress continues and gradually slows through the first year, and most people plateau around 12–18 months. Don't judge the drug by month one — early loss understates where you're heading.

How much weight can you lose in the first month?

Usually modest — a few pounds, some of it water — because you're starting at a low dose that's still being increased. The first month is mostly about your body adjusting and appetite changing, not big scale movement. The bigger losses come as the dose climbs over the following months.

Why am I not losing weight on a GLP-1?

The most common reasons are being early or not yet at the full dose, hitting a normal plateau, a dose that's too low, or habits that quietly drifted (liquid calories, grazing). Sometimes you're losing fat but gaining muscle, so the scale understates it. Occasionally it's genuine lower-response, which is a reason to discuss switching drugs. Almost all of these are addressable with your clinician — don't just quit in frustration.

What is a GLP-1 non-responder?

Someone who loses less than 5% of body weight after a fair trial at a therapeutic dose. In the trials, non-response was fairly uncommon (single-digit percentages on high-dose tirzepatide); in the real world it's more common, with some cohorts reporting about one in six. Because people respond differently to semaglutide versus tirzepatide, a true non-responder on one drug sometimes responds well to the other.

Is real-world weight loss lower than the trials?

Generally yes. Real-world results often land in the high-single-digits to mid-teens rather than the trial's 15–21%, mostly because people stop early, never reach the full dose, or have less structured support than trial participants. The encouraging part is that the main causes — under-dosing and stopping early — are partly within your control.

Why did I plateau?

Because your body reached a new equilibrium at your current dose — metabolism adapts and appetite systems push back until they balance the drug's effect. It's normal and expected (it's where the trial averages were measured), not a sign the drug failed. If you've reached a healthy weight, the plateau is the goal; if you plateaued well short of it, talk to your clinician about dose, drug choice, or lifestyle factors.

Will I gain the weight back if I stop?

For most people, yes, without a plan — a well-known follow-up to the STEP 1 trial found people regained about two-thirds of their lost weight within roughly a year of stopping semaglutide. That's the drug's effect reversing, not a willpower failure. These are generally long-term treatments; the weight you can sustain matters more than the peak loss, and stopping should be a planned, supported taper with a maintenance strategy.

Which GLP-1 is best for weight loss?

By raw average weight loss, tirzepatide (Zepbound) leads at about 21%, ahead of semaglutide (Wegovy) at about 15%, with the oral options lower. But "best" also depends on tolerability, cost, whether you'll inject, and your health profile — the most effective drug you'll actually stay on is the one that works for you. Our tirzepatide vs semaglutide guide compares them in detail.

How much weight loss is considered a success?

Clinically, losing even 5–10% of body weight meaningfully improves blood pressure, blood sugar, cholesterol and related risks — so "success" starts well below the headline averages. The health benefits accrue steadily as you lose, which is why a result in the low-to-mid teens isn't a consolation prize; it's squarely in the range that changes health outcomes.

Can I lose 20% of my body weight on a GLP-1?

Many people do, especially on tirzepatide — more than half of SURMOUNT-1 participants at the top dose lost 20% or more, and about a third lost 25%+. On semaglutide, roughly a third exceeded 20%. It's a realistic outcome for a strong responder at full dose, though not guaranteed — it sits at the better end of the distribution.

Does the weight loss slow down over time?

Yes. The curve is steepest in the middle months as you reach full dose, then gradually slows through the first year, then plateaus around 12–18 months. Slowing loss is the normal shape of the curve, not a problem — it reflects your body approaching a new equilibrium.

How much weight will I lose in 3 months? In 6 months?

It varies widely and depends on how fast you titrate, but a rough pattern: the first few months are slower (you're still reaching full dose), and by around 6 months trial participants had typically lost a substantial share of their eventual total — often past the halfway mark. Treat any specific monthly number as a rough guide; your pace is individual, and early months understate the trajectory.

Does muscle loss affect my results?

Some of rapid weight loss is muscle, and losing muscle lowers your metabolic rate, which can slow fat loss and hurt maintenance. That's why protein and resistance training matter so much — they protect muscle, keep metabolism higher, and improve both your results and your ability to keep the weight off. The scale alone can also understate fat loss if you're building muscle.

Will I lose weight faster on a higher dose?

Generally, higher doses produce more weight loss up to the therapeutic maximum, which is why reaching an effective dose is the biggest controllable factor. But dose increases are titrated gradually to manage side effects, and the right dose is a clinical decision — more isn't automatically better or safe, and your clinician balances effect against tolerability.

How does GLP-1 weight loss compare to surgery?

Bariatric surgery still produces more on average (roughly 25–30%), but tirzepatide at about 21% has narrowed the gap considerably, and the drugs are a less invasive option. For some people surgery remains the better choice; for others the drugs now offer surgery-adjacent results without an operation. It's an individual decision for a clinician who treats obesity.

Where can I compare programs and real costs?

Our ranked comparison scores online weight-loss programs on value, clinical and coaching support, medication options and transparency, and shows each program's real monthly price. Paired with this guide and our complete guide to GLP-1 weight loss online, it helps you choose a program that supports the results you're after.

How much weight will I lose on Ozempic?

Ozempic is semaglutide branded for type 2 diabetes, dosed up to 2 mg (versus Wegovy's 2.4 mg for weight loss). Weight loss on Ozempic tends to run somewhat lower than the ~15% Wegovy average, partly because of the lower dose — often in the high-single-digits to low-teens in percentage terms, varying widely by person. If weight loss is the specific goal, the dedicated weight-loss brands (Wegovy, Zepbound) are what the headline numbers describe.

How much weight will I lose on Mounjaro?

Mounjaro is tirzepatide branded for type 2 diabetes — the same molecule as Zepbound. It produces substantial weight loss, though results in people with diabetes tend to run a bit lower than the ~21% obesity-trial average for Zepbound. For a diabetic patient it's often the covered, affordable path, with strong weight and blood-sugar benefits together.

Is 10% weight loss on a GLP-1 good?

Yes — genuinely. Losing 10% of your body weight meaningfully improves blood pressure, blood sugar, cholesterol and related health risks, and it's a result many older weight-loss drugs couldn't reliably produce. It may be below the headline averages, but it's squarely in the range that changes health outcomes, and paired with improvements in your other health numbers it's a real success, not a shortfall.

Can you lose 100 pounds on a GLP-1?

It's possible for people with a high enough starting weight, because results scale with body size. A 25% loss — achievable for strong responders, especially on tirzepatide — is 100 pounds for someone starting at 400. For someone starting at 220, even a 21% average is about 46 pounds. So "100 pounds" depends heavily on your starting point; the percentage is the consistent part, and pounds follow from where you begin.

How much weight do you lose in the first week?

Very little, and some of what you see is water, not fat — you're at the lowest starting dose, which isn't the effective range yet. The first week is about your body adjusting and appetite beginning to change. Don't read anything into the first week's scale number, up or down; the meaningful loss comes over the following months as the dose climbs.

How long until I see results?

Many people notice appetite changes within the first weeks, and visible weight loss usually becomes clear within the first couple of months as the dose increases, accelerating through roughly months 2–6. If you're judging by the scale, give it two to three months at a rising dose before drawing conclusions — early slow loss is normal and not predictive of your final result.

Does everyone lose weight on a GLP-1?

Most people lose meaningful weight, but not everyone — a minority are lower-responders, and in the real world roughly one in six may not reach 5% loss, often due to stopping early or not reaching full dose. True non-response to an adequate dose is real but uncommon, and because people respond differently to semaglutide versus tirzepatide, it's often addressable by switching drugs rather than a dead end.

What's the maximum weight you can lose?

There's no fixed ceiling, but the practical maximum for most people is set by their body reaching a new equilibrium (the plateau) at an effective dose. In the trials, the top responders lost 25%+ on tirzepatide. Pushing beyond your plateau is limited by biology and dose, which is why the honest framing is a realistic sustainable result, not a theoretical maximum.

Do GLP-1 results stop after a year?

Weight loss slows and typically plateaus around 12–18 months — not because the drug stops working, but because your body reaches a new equilibrium at that dose. The drug keeps holding the line (which is why stopping brings regain); it just shifts from producing loss to maintaining it. A plateau after a year of good loss is the expected, successful transition to maintenance.

How much weight loss should I expect in 6 months on Zepbound?

By around six months, if you've titrated up to an effective dose, you're often past the halfway point of your eventual total — on tirzepatide that can mean a meaningful share of the ~21% final average, though the pace varies widely with how quickly you reached full dose. Six months is still within the steeper part of the curve for many people, with more loss to come before the plateau around 12–18 months. Treat any specific six-month number as a rough guide, not a guarantee.

If I stay on it forever, will I keep losing weight?

No — weight loss plateaus around 12–18 months as your body reaches a new equilibrium at your dose, and staying on the drug then maintains that lower weight rather than driving endless further loss. That's the intended outcome: the drug shifts from producing loss to holding it. Continued loss beyond the plateau generally requires a change (a higher dose or different drug), decided with your clinician, not just more time.

Can switching from Wegovy to Zepbound improve my results?

It can, for some people. Tirzepatide produces more weight loss on average than semaglutide, and people respond differently to the two drugs, so someone who plateaued or under-responded on semaglutide sometimes does better on tirzepatide. It's a common, legitimate clinical move — but it's a decision for your prescriber, who'll manage the switch and dosing. It isn't guaranteed to help, but it's a real option when results stall.

How much of the weight lost is fat versus muscle or water?

Early quick drops include some water. Over time, most of the loss is fat, but a meaningful share can be muscle if you don't protect it — which is exactly why protein and resistance training matter. The proportion that's muscle versus fat is partly in your control: adequate protein and strength work shift the balance toward losing fat and keeping muscle, which also protects your metabolism and your long-term maintenance.

Is it normal to lose weight slowly at first?

Completely normal, and expected. You start at the lowest dose, which isn't the effective range, and it's increased gradually over months — so early loss is modest by design. The curve back-loads, with the steeper losses coming once you reach higher doses. Slow early loss is not predictive of a poor final result; judging the drug in the first few weeks is the most common mistake people make.

Does a plateau mean the drug stopped working?

No. A plateau means your body reached a balance point at your current dose, where the drug's appetite suppression and your body's weight defense even out. The drug is still working — it's holding your lower weight, which is why stopping would bring regain. A plateau is the normal transition from losing to maintaining, not a sign of failure or tolerance.

A plain-language glossary

• Percentage body weight loss: how weight loss is measured in trials — a share of your starting weight, so it scales to your size. "15%" of 200 lb is 30 lb.
• Average (mean) weight loss: the center of a wide spread, not a number everyone hits. Half of people do better, half worse.
• Responder bands: the share of people reaching thresholds like ≥5%, ≥10%, ≥15%, ≥20% loss — a truer picture than the average alone.
• Non-responder: someone losing less than 5% after a fair trial at a therapeutic dose. Often responds to a different GLP-1.
• Titration: the gradual increase of the dose over months to limit side effects. The trial averages are at the full post-titration dose.
• Plateau: the point (often 12–18 months) where weight loss stops as your body reaches a new equilibrium at the current dose. Normal, not failure.
• Set point: the weight your body defends through appetite and metabolism. GLP-1s shift it down; stopping lets it drift back up.
• STEP 1 / SURMOUNT-1 / OASIS 4 / ATTAIN-1: the pivotal trials behind semaglutide, tirzepatide, oral semaglutide and orforglipron, respectively.

How we sourced this

The weight-loss figures here come from the pivotal phase 3 trials, published in peer-reviewed journals: STEP 1 for semaglutide, SURMOUNT-1 for tirzepatide, OASIS 4 for oral semaglutide, and ATTAIN-1 for orforglipron, with mechanism and context from Harvard Health and the National Institute of Diabetes and Digestive and Kidney Diseases. Responder-band percentages reflect the trials' reported threshold rates; we've given them as approximate because exact figures vary with the analysis method. Real-world and regain figures reflect published follow-up and cohort research; because these vary by population and setting, we describe them as ranges and patterns rather than single numbers. These are averages from specific study populations and may not reflect your result — the only person who can tell you what to expect for your situation is a clinician who knows your history.

The bottom line

So, how much weight can you lose on a GLP-1? Enough to change your health and, for many people, their lives — averages of roughly 15% on semaglutide and 21% on tirzepatide, with the oral options a step behind, and a real chance of 25%+ for strong responders at full dose. Those are surgery-adjacent numbers from a prescription, which is why these drugs reset what's possible in obesity medicine.

But the number that matters for you isn't the headline average — it's where you land in a wide distribution, how much of the trial result survives into real life, and how much you can sustain. The honest version: expect somewhere in the double digits if you reach an effective dose and stay on it, plan for the possibility you respond less than average, do the controllable things (dose, consistency, protein, strength training, support) that pull your result toward the top of the range, and understand that keeping the weight off is a long-term project, because stopping tends to bring it back. Set expectations on the real distribution rather than the best-case headline, and you're far more likely to be satisfied with a result that is, by any historical standard, remarkable.

If there's one idea to carry out of all these numbers, it's this: the average is a starting point for your expectations, not a verdict on your future. The trials tell you what's achievable and how likely each level of result is; your drug choice, the dose you reach, your consistency, and the habits you build around the medication decide where in that range you land. Plenty of people beat the average; plenty fall below it; almost everyone who reaches an effective dose and stays on it loses an amount of weight that would have been considered extraordinary a few years ago. Aim for the middle of the realistic range, do the controllable things well, count the health wins alongside the pounds, and plan for the long haul — and the odds are genuinely in your favor.

When you're ready to turn the numbers into a plan, our ranked comparison and complete guide to GLP-1 weight loss online help you choose a program built to get you results you can keep — not just a prescription, but the support that moves real-world outcomes toward the trial ones.